Why the study?
The SAPIEN 3 addressed limitations of the SAPIEN XT, but whether these altered features translated into improved real-world outcomes after transfemoral TAVI required evaluation.
Does the SAPIEN 3 valve improve survival and reduce complications compared to the SAPIEN XT valve in patients undergoing transfemoral TAVI?
Does the SAPIEN 3 valve improve survival and reduce complications compared to the SAPIEN XT valve in patients undergoing transfemoral TAVI?
Answers are grounded in this paper and cite their sources.
The newer-generation SAPIEN 3 valve improves 1-year survival and reduces paravalvular leak and stroke compared to SAPIEN XT, though at the cost of increased permanent pacemaker implantation.
BACKGROUND: The SAPIEN 3 (S3) addresses several limitations of the SAPIEN XT (SXT) for the performance of transfemoral (TF-) balloon expandable transcatheter aortic valve implantation (TAVI). OBJECTIVES: We aimed to determine whether their altered features translate into improved outcomes in a real-world TF-TAVI patient population. METHODS: Data for 3,314 patients were extracted from the European registries SOURCE-XT and SOURCE-3. Patients were propensity-score (PS) matched (n = 1,169/group). RESULTS: In the PS matched comparison, device success was higher in the S3 (99.2%) compared to the SXT group (98.2%; p = .04). S3 patients experienced a lower rate of procedural death (0.7 vs. 2.6%; p = .0004), moderate/severe paravalvular leakage (PVL; 1.4 vs. 5.5%; p < .0001), and procedure-related stroke (1.2 vs. 2.4%; p = .04) while higher rates of mean aortic valve gradients ≥20 mmHg, and new permanent pacemaker implantations were seen. At 30 days a lower rate of all-cause mortality was seen (2.1% vs. 4.3%; p = .003), which was preserved after 1 year (10.7% vs. 14.9%; p = .002). A Cox regression predicting 1-year mortality resulted in a hazard ratio of 0.684 in favor of S3 (p = .0026). The same was true of stroke (2.8% vs. 5.7%; p = .0007), and moderate/severe PVL (2.7 vs. 7.3%; p = .0002) at 1 year. The rate of new pacemaker implantations (13.6% vs. 9.5%; p = .001) and NYHA III/IV (12.8 vs. 8.6%; p = .004) was higher with the S3. CONCLUSIONS: The improved features of the S3 appear to translate into improved survival and reduced rates of adverse complications, with the exception of a higher rate of new pacemaker implantations.
No takes yet. Share an insight, caveat, or question.
Schymik et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: